ENZ earnings

FARMINGDALE, NY, April 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo Biochem" or the "Company"), a leading biosciences and diagnostics company, today announced that its special meeting of shareholders (the "Special Meeting") to consider and vote on a proposal to approve the sale (the "Asset Sale") of substantially all the assets and assignment of certain liabilities of its clinical laboratory business to Laboratory Corporation of America Holdings, a Delaware corporation ("Labcorp") and adopt the Asset Purchase Agreement, dated as of March 16, 2023 (as such agreement may be amended from time to time, the "Asset Purchase Agreement"), by and among the Company, Enzo Clinic

- Enzo Life Sciences reports revenue of $7.1 million and 9% growth in Q1 FY 2023, excluding FX - Engagement with investment bank to provide advisory services including the evaluation of strategic alternatives for the Company is progressing well. - Continuing to make progress in market expansion of the current product portfolio, commercialization of the Company's offerings, and optimization of the clinical service segment. Conference call and live webcast scheduled for tomorrow, Tuesday, December 13, 2022 at 8:30 am (ET) FARMINGDALE, N.Y., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported operating res

Conference Call and Webcast Scheduled for December 13th, 8:30 AM ET New York, NY, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report first quarter fiscal 2023 financial and operating results after the market close on Monday, December 12, 2022. The Form 10-Q filing will be followed by a live audio webcast and conference call the next day at 8:30 AM ET. To participate in the conference call, please dial the following numbers prior to the start of the call or click the webcast link below to participate over the internet: Tuesday, December 13th @ 8:30 am ET Domestic

NEW YORK, NY, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company"), a leading biosciences and diagnostics company, today announced that its Annual Shareholders' Meeting will be held on January 31, 2023.  Shareholders must submit proposals and/or director nominations in connection with meeting no later than November 18, 2022 to be considered timely. About Enzo Biochem Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company,

- Enzo Life Sciences reports revenue of $32.6 million and 8% growth in FY 2022, net of FX - Company successfully launched AMPIVIEW™ gene expression platform powered by LoopRNA™ ISH technology - Continues to engage with previously announced investment bank to provide advisory services including the evaluation of strategic alternatives for the Company - Under the leadership of a new CEO, Enzo has been reorganized to leverage on our ‘focused return' strategy including the appointment of new executive management and augmenting the sales team to position the Company for continued growth in a cost-effective manner Conference call and live webcas

Conference Call and Webcast Scheduled for October 14, 2022, 8:30 am ET NEW YORK, NY, Oct. 10, 2022 (GLOBE NEWSWIRE) --  Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report fourth quarter 2022 financial results on Friday, October 14, 2022, premarket. The announcement will be followed by a live audio webcast and conference call the same day at 8:30 am Eastern Time. Please see additional details below: Friday, October 14th @ 8:30 am ETDomestic:         877-407-0792International:    201-689-8263Conference ID: 13733235 Webcast:           Registration Link -- Click Here About Enzo Biochem Enzo Biochem

Third quarter revenue of $26.2 million declined sequentially and year over year due to the anticipated waning of COVID-19 volumes and the economic shutdowns in Asia Received approval from New York State Department of Health for its AMPIPROBE® HPV Molecular Diagnostic tests available on the GENFLEX® platform, as well as approvals on additional sample types around chlamydia, gonorrhea and trichomonas Appointed and hired several new executive management team members in the quarter to position the Company for continued growthEngaged world class investment bank to provide advisory services including the evaluation of strategic alternatives for the Company, its Enzo Clinical Lab and Enzo Life Scie

NEW YORK, NY, June 06, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report third quarter 2022 financial results on Thursday, June 9, 2022, after the market close. The announcement will be followed by a live audio webcast and conference call on Friday, June 10, 2022 at 8:30 am Eastern Time. Please see additional details below: Friday, June 10th  @ 8:30 am ETDomestic:                    877-407-0792International:               201-689-8263Conference ID:           13730182 Webcast:                     Registration Link -- Click Here About Enzo Biochem   Enzo Biochem is a pioneer in molecular dia

Conference Call and Webcast Scheduled for June 9, 2022, 4:30 pm ET NEW YORK, NY, June 02, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report third quarter 2022 financial results on Thursday, June 9, 2022, after the market close. The announcement will be followed by a live audio webcast and conference call at 4:30 pm Eastern Time. Thursday, June 9th  @ 4:30 pm ETDomestic:                    877-407-0792International:               201-689-8263Conference ID:           13730182 Webcast:                     Registration Link -- Click Here About Enzo Biochem   Enzo Biochem is a pio

Second quarter revenue of $34.0 million increased 28% sequentially and8% year-over-year compared to FY2021 Enzo Biochem posted highest quarterly revenue in history of the Company Enzo Life Science revenue reached $10.4 million, an increase of 39% year over yearReceived LDT regulatory approval from New York State for CT/NG/TV molecular testsQ2 FY22 product margin increased to 49% compared to 40% in Q1 FY22 and 47% Q2 FY21CEO advances strategy to focus on core competencies while strengthening and augmenting management team Conference call and live webcast scheduled for today,Monday, March 14, 2022 at 4:30 pm (ET) NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc (NYSE:ENZ)

Conference Call and Webcast Scheduled for March 14, 2022, 4:30 pm ET NEW YORK, NY, March 08, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report second quarter 2022 financial results on Monday, March 14, 2022, after the market close. The announcement will be followed by a live audio webcast and conference call at 4:30 pm Eastern Time. Monday, March 14th  @ 4:30 pm ETDomestic:                    877-407-0792International:               201-689-8263Conference ID:           13727738 Webcast:                     Registration Link -- Click Here About Enzo Biochem   Enzo Biochem is a pioneer in m

1Q FY 2022 revenues of $26.5 million vs. $24.8 million in 4Q FY 2021, representing a 7% sequential increaseCompany appoints Hamid Erfanian as Chief Executive Officer Consolidated manufacturing footprint at state-of-the-art Farmingdale, NY campus to enhance operational efficiencies Conference call and live webcast scheduled for today,Wednesday, December 15, 2021 at 4:30 pm (ET) NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) --  Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported financial results for the first quarter ended October 31, 2021 and provided a business update on recent corporate and operational developments. This quarter once again reflects

Conference Call and Webcast Scheduled for December 15, 2021, 4:30 pm ET NEW YORK, NY, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report first quarter 2022 financial results on Wednesday, December 15, 2021, after the market close. The announcement will be followed by a live audio webcast and conference call at 4:30 pm Eastern Time. Wednesday, December 15th  @ 4:30 pm ETDomestic:                    877-407-0792International:               201-689-8263Conference ID:             13725234Webcast:                      Registration Link -- Click Here About Enz

FY 2021 revenues of $117.7 million vs. $76.0 million, an increase of 55% YoY 4Q 2021 revenues of $24.8 million vs. $19.5 million a year ago, an increase of 27%FY 2021 EPS of $0.16 per share compared to a year ago loss of $(0.60)4Q 2021 EPS of $0.07 per share vs. ($0.07) in the year-ago quarter Expanded FDA Emergency Use Authorization (EUA) for Enzo's SARS-CoV-2 testing platform, including use of Enzo extraction method that reduces time to obtain results and allows more test runs on a single instrumentConsolidated manufacturing footprint with the closure of Ann Arbor and upgrade of Farmingdale, NY campus to enhance operating efficienciesGoTestMeNow direct-to-consumer testing service to launch

Conference Call and Webcast Scheduled for October 12, 2021, 8:30 am ET NEW YORK, NY, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report fourth quarter and fiscal year 2021 financial results on Tuesday, October 12, 2021, before the market open. The announcement will be followed by a live audio webcast and conference call at 8:30am Eastern Time.  Tuesday, October 12th@ 8:30am ET Domestic:               877-407-0792 International:             201-689-8263 Conference ID:          13723500 Webcast:                   http://public.viavid.com/index.php?id=146658 About Enzo BiochemEnzo Biochem is